Latest Content

Week 96 data from the LATA trial show Cabenuva was superior to daily oral therapy in adolescents with HIV, while new real-world OPERA cohort data reinforce comparable effectiveness in adults, both presented at AIDS 2026.

An oral antiviral candidate blocked airborne and direct-contact transmission of a measles-like virus in ferrets, offering a potential new outbreak-control tool as US measles cases hit a 35-year high.

Atea Pharmaceuticals' bemnifosbuvir/ruzasvir combination met its primary endpoint of noninferiority to sofosbuvir/velpatasvir in the phase 3 C-BEYOND trial, achieving comparable cure rates for hepatitis C with as little as 8 weeks of treatment.

2026 clinical practice guidelines developed by the IDSA and ESCMID address risk stratification, diagnosis and management of S aureus bacteremia.

Several combination products are currently in development for people with HIV. Here is a review of these treatments.

Despite competing national crises drawing attention elsewhere, experts warn that the ongoing H5N1 avian influenza outbreak in birds, cattle, and humans in the United States highlights critical gaps in surveillance, worker protections, and pandemic preparedness that must be addressed to prevent a future pandemic.

FDA's acting deputy commissioner for food said the US food supply remains safe even as CDC-confirmed cyclosporiasis cases climbed past 11,000, while a new survey found nearly half of Americans don't trust the agency to manage the outbreak.

Sharon Nachman, MD, chief of pediatric infectious disease at Stony Brook Children's Hospital, explains why local resistance data, not just global forecasts, should drive today's empiric antibiotic choices in children.

A global surveillance study of more than 100,000 pediatric bacterial isolates found rising antimicrobial resistance across all regions from 2004 to 2022, with forecasts projecting continued increases in resistance to last-line antibiotics through 2035.

Shionogi's XOCOVA (ensitrelvir) is now available in the United States as the first oral option to help prevent COVID-19 after exposure, following phase 3 SCORPIO-PEP trial data showing a 67% reduction in symptomatic infection risk.

Three concurrent studies identify T cell exhaustion and Th2 skewing as distinct immune phenotypes in disseminated coccidioidomycosis, with targeted immunomodulation producing dramatic clinical responses in patients who had failed standard antifungal therapy.

ViiV Healthcare's 2-drug Dovato regimen met its noninferiority end point against Gilead's 3-drug Biktarvy in the first head-to-head randomized trial comparing the 2 in treatment-naive adults with HIV.

As the Cyclospora outbreak continues, clinicians and public health advocates are highlighting a secondary risk: antibiotic treatment for the parasitic infection can disrupt the gut microbiome and raise the risk of C diff.